All sponsors

CatalYm GmbH

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS5
PHASE 3 / 2-31
RECRUITING4
READOUTS ≤12 MONTHS0
Open CatalYm GmbH on the live radar map →
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
GDFATHER
NCT04725474
P1/2Active, not recruitingSolid Tumor, Adult1992028-04-30 (+59 mo)
Visugromab
NCT07098988
P2RecruitingMetastatic Non-Squamous Non-Small Cell Lung Cancer; Adult Solid Tumor1072029-03-31
GDFATHERHCC01
NCT07219459
P2RecruitingUnresectable or Metastatic Hepatocellular Carcinoma; Child-Pugh A Hepatocellular Carcinoma1042029-09
Visugromab RDE (recommended dose for expansion)
NCT07246863
P2RecruitingMetastatic Non-Squamous Non-Small Cell Lung Cancer; Adult Solid Tumor1312029-10-01
VINCIT
NCT07112196
P2/3RecruitingCancer-associated Cachexia5182029-12